eClinical Technology and Industy News

Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of Hematology

  • ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patients with Relapsed/Refractory Large B Cell Lymphoma
  • ALPHA Study Abstract Selected for Poster Presentation Continues to Show Durability of Responses to ALLO-501 in Patients with Non-Hodgkin Lymphoma
  • UNIVERSAL Study Abstract Selected for Oral Presentation Reports Meaningful Activity of a Single Dose of ALLO-715 in Patients with Relapsed/Refractory Multiple Myeloma
  • Presentations Scheduled for December 13, 2021

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today announced that it will present updated data from its blood cancer portfolio at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place December 11 – 14, 2021. Allogene will have two oral presentations, one focused on the Phase 1 ALPHA2 study of ALLO-501A in large B-cell lymphoma (LBCL) and one on the Phase 1 UNIVERSAL single dose cohorts of ALLO-715 in relapsed/refractory multiple myeloma (MM). The Company will also present data on the Phase 1 ALPHA study of ALLO-501 in relapsed/refractory non-Hodgkin’s lymphoma (NHL) during a poster session. Updated data will be included in the oral and poster sessions on December 13, 2021.

“We are looking forward to sharing additional data from our lead AlloCAR T programs at the ASH Annual Meeting,” said Rafael Amado, M.D., Executive Vice President of Research & Development and Chief Medical Officer of Allogene. “We believe that our allogenic CAR T therapies have the potential to enable a new and more hopeful future for blood cancer patients who are in need of alternative treatment options. The findings within our ASH abstracts continue to support the promise and differentiation of our platform as we look ahead to future development.”

Phase 1 ALPHA2 Trial (ALLO-501A) Abstract
ALLO-501A is a next generation anti-CD19 AlloCAR T engineered without the rituximab recognition domains in ALLO-501. The Phase 1 dose escalation portion of the ALPHA2 trial in relapsed/refractory LBCL was designed to confirm that the profile of ALLO-501A is similar to ALLO-501 prior to advancing ALLO-501A into a pivotal Phase 2 trial.

As of the ASH abstract data cutoff date of July 9, 2021, 12 patients (six each in single dose and consolidation dose cohorts) were treated with follow-up for response at dose levels from 40 to 120 X 106 CAR+ cells of ALLO-501A. Consolidation dosing appeared to be well tolerated with the potential for enhanced efficacy compared to a single dose of ALLO-501A. In the consolidation cohort, both the overall response rate (ORR) and complete response (CR) rate were 67% with all three partial responses (PRs) converting to CR following consolidation. All four consolidation patients who achieved a CR remained in CR as of the data cut-off.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives